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Abstract Background: Acute severe
asthma induces marked alterations in
respiratory mechanics, characterized
by a critical limitation of expiratory
flow and a heterogeneous and re-
versible increase in airway resistance,
resulting in premature airway closure,
lung, and chest wall dynamic hy-
perinflation and high intrinsic PEEP.
Discussion: These abnormalities in-
crease the work of breathing and can
lead to respiratory muscle fatigue and
life-threatening respiratory failure, in
which case mechanical ventilation
is life-saving. When instituting me-
chanical ventilation in this setting,
a major concern is the risk of wors-
ening lung hyperinflation (thereby
provoking barotrauma) and induc-
ing or aggravating hemodynamic
instability. Guidelines for mechanical
ventilation in acute severe asthma
are not supported by strong clinical
evidence. Controlled hypoventilation
with permissive hypercapnia may
reduce morbidity and mortality com-
pared to conventional normocapnic
ventilation. Profound pathological
alterations in respiratory mechanics
occur during acute severe asthma,
which clinicians should keep in mind
when caring for ventilated asthmat-
ics. Conclusion: We focus on the
practical management of controlled
hypoventilation. Particular attention
must be paid to ventilator settings,
monitoring of lung hyperinflation,
the role of extrinsic PEEP, and ad-
ministering inhaled bronchodilators.
We also underline the importance
of deep sedation with respiratory
drive-suppressing opioids to main-
tain patient-ventilator synchrony
while avoiding as much as can be
muscle paralysis and the ensuing
risk of myopathy. Finally, the role
of noninvasive positive pressure
ventilation for the treatment of respi-
ratory failure during severe asthma is
discussed.
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Introduction
According to consensus guidelines, acute severe asthma is
defined by the occurrence of a rapid exacerbation charac-
terized by the presence of one or more of the following fea-
tures: accessory muscle activity, paradoxical pulse exceed-
ing 25 mmHg, heart rate greater than 100 beats/minute,
respiratory rate greater than 25–30 breaths/minute, limited
ability to speak, peak expiratory flow rate or forced expi-
ratory volume in 1 s less than 50% of predicted, and an
arterial oxygen saturation less than 91–92% [1].
In contrast to usual practice in other forms of respira-
tory failure, mechanical ventilation in acute severe asthma
is often delayed and is used mostly as an ultimate mean
when all conventional medical treatments have failed. In
patients admitted to medical intensive care units for acute
severe asthma the rate of intubation varies widely between
studies (2–70%, mean approx. 30% [1]). A major concern
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in initiating mechanical ventilation in this setting relates to
technical difficulties and to the risk of complications [2].
To understand why this is the case it is important to bear in
mind the consequences of severe bronchial obstruction on
respiratory mechanics. These are reviewed in the first part
of this contribution. We then outline the practical aspects of
mechanical ventilation in severe asthma, with particular at-
tention paid to ventilatory mode, monitoring of lung hyper-
inflation, reasons for using or not using extrinsic PEEP, ad-
ministration of inhaled β-adrenergic agents, and protective
effects of controlled hypercapnic hypoventilation. We also
cover the management of sedation, analgesia, and muscle
paralysis.
Respiratory mechanics
Acute severe asthma is characterized by pulmonary hyper-
inflation, with an increase in functional residual capacity
of up to twice the normal values in very severe cases [3].
The mechanism of this hyperinflation consists in the crit-
ical limitation of the expiratory flow [4], due mainly to
two factors. First, the driving forces for expiratory flow
are reduced due to an abnormally low pulmonary elastic
recoil of unclear mechanism [5, 6] and to an abnormally
high outward recoil of the chest wall generated by the per-
sistent activation of the inspiratory muscles during expira-
tion [7]. Second, resistance to airflow is strongly increased
because of severely reduced airway caliber and perhaps
also expiratory narrowing of the glottic aperture [8]. These
particular conditions induce a prominent increase in the
mechanical time constant of the respiratory system and
a markedly prolonged expiration so that the following in-
spiration starts before static equilibrium is reached. Conse-
quently the end-expiratory alveolar pressure remains posi-
tive, a phenomenon known as auto-PEEP or intrinsic PEEP
(PEEPi) [9, 10].
The level of PEEPi and the degree of hyperinflation
increase with the tidal volume, time constant of the respi-
ratory system, and shortening of expiratory time. Because
of the uneven distribution of bronchial obstruction both
anatomical (due to secretions, edema, bronchospasm)
and dynamic (due to the external compression exerted
on the distal airways by intrathoracic positive pressure
during expiration), the lung is extremely inhomogeneous
during acute severe asthma [11]. Schematically, the
asthmatic lung can be described as consisting of four
parallel compartments (Fig. 1): compartment A refers to
the portion of the lung without bronchial obstruction nor
hyperinflation; in compartment B the airways are entirely
obstructed during the whole respiratory cycle (mucous
plugging); in compartment C obstruction appears only
during expiration, inducing alveolar hyperinflation and
high PEEPi; in compartment D partial obstruction of the
airways is present throughout the respiratory cycle causing
a lesser extent of alveolar hyperinflation and PEEPi than
Fig. 1 Effect of varying amounts of
airway osbstruction on
end-expiratory alveolar volumes and
pressures
Fig. 2 Expected distribution of the
tidal volume during
positive-pressure mechanical
ventilation in the context of
inhomogeneous obstruction
in compartment C. In such a system characterized by
variable time constants most of the tidal volume delivered
by positive pressure ventilation goes to compartment A,
which represents lung parenchyma with almost normal
mechanical characteristics (Fig. 2). Since such “mechan-
ically normal” areas represent only a small fraction of
the total asthmatic lung, these conditions resemble those
created by overdistending a tiny normal lung with a large
tidal volume (the “baby lung” concept [12]). Several
detrimental consequences may ensue: (a) abnormal dis-
tribution of ventilation-perfusion ratio due to diversion
of blood perfusion to normally ventilated lung zones,
(b) increased risk of barotrauma, and (c) impedance to
venous return with hemodynamic compromise, shock, and
cardiocirculatory arrest [13].
Therefore, when ventilating patients with acute severe
asthma, the crucial objective is to prevent any further in-
crease in lung hyperinflation. In this respect the system-
atic observations made by Tuxen and Lane [14] more than
15 years ago are still valid. These authors studied eight pa-
tients suffering from acute airway obstruction, five from
acute severe asthma and three from acute exacerbation of
chronic obstructive pulmonary disease. All patients were
intubated, ventilated using volume-controlled mode, and
paralyzed. Dynamic hyperinflation was evaluated during
a prolonged apnea of 60 s by measuring the exhaled vol-
ume starting from the end of inspiration. From these obser-
vations several statements can be made: (a) For any given
value of minute ventilation (VE), end-inspiratory lung dis-
tention is minimized by a combination of low tidal volume
(VT) and high respiratory rate (Fig. 3, compare adjacent
columns within a group of three). (b) For any given value
of VT hyperinflation is minimized by increasing the expi-
ratory time (TE), which is achieved by reducing respiratory
rate and therefore VE (Fig. 3, compare groups of 3 columns
with one another).
When keeping VT, respiratory rate, and VE constant,
the TE remains adaptable and can be increased at the
503
Fig. 3 Effect of respiratory rate and tidal volume variations on air-
way pressures and lung volumes during mechanical ventilation of
acute severe asthma. FRC Functional residual capacity; Ppeak peak
inspiratory pressure; Pplat end-inspiratory plateau pressure; RR res-
piratory rate; VT tidal volume; TE expiratory time; VE minute venti-
lation. All conditions are for a square inspiratory flow of 100 l/min.
(Data with permission from [3])
expense of the inspiratory time (TI). In conditions of high
levels of VE (16 and 26 l/min), increasing inspiratory
flow and thus reducing TI allows a decrease in lung
hyperinflation (Fig. 4, compare the adjacent columns
within a group of three). However, with a lower VE
Fig. 5 End-expiratory flow, peak
inspiratory pressure (Ppeak),
end-inspiratory plateau pressure (Pplat)
and auto-PEEP (PEEPi) in asthmatic
patients ventilated with close to or less
than 10 l/min minute ventilation (VE).
VE was progressively reduced and
expiratory time (TE ) progressively
increased by lowering cycling frequency
(RR) at constant VT and inspiratory
time, using a square inspiratory flow
waveform. Note the trivial effect on
dynamic hyperinflation (as reflected by
Pplat) of halving VE (from 7.4 to
3.7 l/min) and thus more than doubling
TE (from 4.5 to 9.5 s) which is related to
the very low end-expiratory flow rates in
these conditions (< 40 ml/s). (Adapted
from [5])
Fig. 4 Effect of inspiratory flow variations on airway pressures and
lung volumes during mechanical ventilation in acute severe asthma.
FRC Functional residual capacity; Ppeak peak inspiratory pressure;
Pplat end-inspiratory plateau pressure; RR respiratory rate; VT tidal
volume; TE expiratory time; VE minute ventilation. All conditions
are for a square inspiratory flow of 100 l/min. (Data with permission
from [3])
(10 l/min) and a TE somewhat above 4 s, the impact on
hyperinflation (as reflected by end-inspiratory plateau
pressure, Pplat) of further lengthening TE at the expense
of TI becomes negligible. The relative futility of increas-
ing TE beyond 4 s in ventilated asthmatics receiving
10 l/min VE or less has been recently emphasized by
Leatherman and colleagues [15], who pointed out the very
low end-expiratory airflows prevalent in such conditions
(Fig. 5).
504
Ventilatory techniques
Indications for intubation
The decision to intubate is based essentially on clinical
judgement. Progressive exhaustion and patient fatigue
despite maximal therapy together with altered level of con-
sciousness are indications for intubation. In the absence
of respiratory arrest maintaining adequate oxygenation
(and oxygen transport) with supplemental oxygen is
seldom a problem even in very severe asthma and is
a relatively uncommon reason for intubation. If the patient
is cooperative, hypercapnia and fatigue do not necessarily
mandate intubation because noninvasive ventilation may
be an option (see below).
Recommendations for ventilator management
The primary focus must be on avoiding excessive airway
pressure and minimizing lung hyperinflation. To achieve
this goal it is often necessary to hypoventilate the patient
and thus to tolerate hypercapnia. This strategy, initially
proposed by Darioli and Perret [16] in 1984, is termed
“controlled hypoventilation” or “permissive hypercap-
nia” [17]. It differs from the conventional ventilation as
practiced two decades ago which, by trying at all costs to
restore a normal PaCO2, imposed on the lung a mechanical
stress potentially more dangerous to the patient than is
respiratory acidosis.
Table 1 summarizes the proposed initial settings of the
ventilator. From the data presented above (Figs. 3, 4, 5),
the way to minimize hyperinflation essentially consists in
keeping VE down (i.e., ≤ 10 l/min in the average adult pa-
tient) and TE up (≥ 4 s). Once a ventilatory pattern consis-
tent with these goals has been achieved, there is probably
little to be gained by further fiddling with machine settings.
This statement is exemplified by the trivial effect on PEEPi
and Pplat of halving VE (from 7.4 to 3.7 l/min) and more
than doubling TE (from 4.5 to 9.5 s) shown in Fig. 5 [5].
At any given value of VT and respiratory rate, increasing
inspiratory flow allows TI to be reduced and thus TE to be
Table 1 Initial ventilator settings in intubated asthmatic patients
Ventilatory parameters Settings
Mode Volume-controlled ventilation
Minute ventilation <10 l/min
Tidal volume 6–10 ml/kg ideal body weight
Respiratory rate 10–14 cycles/min
Plateau pressure <30 cmH2O
Inspiratory flow rate 60–80 l/min
Inspiratory flow waveform Decelerating waveform
Expiratory time 4–5 s
PEEP 0 cmH2O
FIO2 To an SaO2 of >90%
increased. In this respect values of 60–80 l/min (Table 1)
are optimal, while only marginal gains are to be expected
from higher inspiratory flow rates (e.g., TE is generally
augmented by ≤ 1 s if inspiratory flow rate is increased
from 60–80 to 100–120 l/min, which is largely insufficient
to significantly impact on hyperinflation).
Some specific issues related to the ventilatory manage-
ment of severely asthmatic patients are discussed below.
Ventilatory mode
Controlled ventilation is normally required following
intubation because of the deep sedation (with or without
muscle paralysis, see below) that is necessary to avoid
patient-ventilator asynchrony and to manage controlled
hypoventilation. No consensus exists in terms of what
mode of ventilation should be used later. Volume-
controlled ventilation is currently usually preferred,
pressure-control being discouraged for the following
reasons. First, in conditions of fluctuating high airway
resistance and PEEPi, pressure-control entails the risk
of variable tidal volume with sometimes unacceptably
low alveolar ventilation. With this mode, furthermore,
severe reventilation alkalosis may develop if airway
obstruction subsides rapidly. Volume-control obviates
these disadvantages but mandates careful monitoring of
inflation pressures (see below).
The optimal inspiratory flow waveform to be used in
asthmatics on volume-controlled ventilation is not entirely
clear. At identical levels of VT, TI and Pplat a square wave
results in a higher peak inspiratory pressure (Ppeak) than
does a decelerating wave (i.e., flow-resistive pressure, or
Ppeak-Pplat, is greater with the former flow pattern). This
consideration has limited clinical relevance because due to
its important resistive component Ppeak does not reflect
alveolar distension pressure in most of the lung [18]. Nev-
ertheless, a lower Ppeak may mean less overdistention of
alveoli distal to the least obstructed airways, as such the
most exposed to high pressure in the central airways (unit
A in Fig. 2). A more practical and important reason to min-
imize Ppeak and thus to prefer the decelerating over the
square waveform is that delivery of the full VT as set on
the ventilator is less easily interrupted by opening of the
pop-off safety valve, making up for a steadier VE.
Monitoring of hyperinflation
Tuxen and colleagues [14] have proposed to monitor
dynamic hyperinflation by measuring the volume exhaled
from end-inspiration to static functional residual capacity
in the course of a 60 s apnea (VEI). In 22 patients me-
chanically ventilated for acute severe asthma VEI values
above 20 ml/kg were associated with an increased risk of
hypotension and barotrauma [19]. Based on these data
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the authors tested in eight patients a ventilatory strategy
able to maintain VEI at 20 ml/kg or less and thus to reduce
the complications related to mechanical ventilation while
avoiding excessive hypoventilation [20]. However, the
need for complete muscle relaxation, with its corollary
of potential complications (see below), does not justify
the use of VEI as a practical clinical tool. In addition, the
theoretical advantage of VEI over other clinical variables
as a predictor of the risk of barotrauma is supported
only by few observations [18]. Of note, the measurement
of PEEPi by the end-expiratory occlusion technique
sometimes yields unexpectedly low values, presumably
reflecting airway closure [21]. In practical terms Pplat
remains the recommended variable for the monitoring
of lung hyperinflation during mechanical ventilation in
general [22] and in asthmatic patients in particular [15].
It must be underscored that an end-inspiratory pause of
several seconds is required for an accurate measurement
of Pplat, due to the prolonged equilibration time of the ex-
tremely heterogeneous asthmatic lung. Also, the recorded
value is only valid in absence of leaks in the system
(endotracheal tube cuff, valve activated for end-inspiratory
occlusion). The clinical threshold value of Pplat has been
fixed at 30 cmH2O. This is based, first, on the general
guidelines concerning mechanical ventilation [22] and,
second, on data reported by Leatherman [18]; in this series
of 90 patients ventilated for acute severe asthma the mean
Pplat was 26 cmH2O with a rate of barotraumas of 4%. As
noted above, Ppeak, in contrast to Pplat, is not useful for
assessing lung hyperinflation in asthmatic patients because
depends strongly on airway resistance and inspiratory flow
setting (Fig. 4). In conclusion, the measurement of Pplat
(care being taken to use an end-inspiratory pause of suffi-
cient duration) probably constitutes the best assessment of
both hyperinflation and the risk of barotrauma in patients
on mechanical ventilation for severe asthma.
The role of extrinsic PEEP
Tuxen [23] measured the effect of progressive PEEPe on
lung volumes and pressures in six patients with severe air-
way obstruction. The gradual increase in PEEPe from 5
to 15 cmH2O induced a proportional and significant in-
crease in end-inspiratory volume and of functional resid-
ual capacity, paralleled by an elevation in Pplat. In addi-
tion, an elevation in both esophageal and central venous
pressures with a concomitant reduction in cardiac output
and blood pressure was observed. These data are consistent
with observations by McFadden and colleagues [24] indi-
cating that at the height of an asthmatic attack the predom-
inant site of increased resistance to airflow is located in
the central, noncollapsible airways, and that the transmural
pressure of peripheral, collapsible bronchi and bronchioles
therefore remains positive throughout expiration. In these
conditions passive exhalation is not flow limited (i.e., there
is no “waterfall effect”), and the applied PEEPe extends all
the way up to the alveoli. Thus during controlled ventila-
tion in asthma there is no benefit from PEEPe regarding
work of breathing since patients are passive. Furthermore,
because these patients may not have expiratory flow lim-
itation (unlike those with chronic obstructive pulmonary
disease), the institution of PEEPe may only increase end-
expiratory lung volume [9, 25].
In contrast, low levels of PEEPe may be useful at
the resolution phase when inspiratory muscle activity
resumes and the patient triggers the ventilator. At this
stage the resistance of central airways normalizes first
while protracted obstruction may persist in the periphery
of the lung [24], creating conditions for expiratory flow
limitation, as occurs during exacerbation of chronic ob-
structive pulmonary disease [26]. Therefore when patients
are triggering and especially during weaning PEEPe may
decrease muscle effort required to trigger the ventilator.
Keeping in mind that the existence of the waterfall
effect is not guaranteed, and also that flow-limited and
flow-unlimited pathways may coexist in these conditions,
a prudent trial of low level PEEPe (≤ 8 cmH2O) can
be advocated, with titration for patient comfort under
close monitoring of airway and blood pressures [25].
Frequent reassessment is essential because the adequate
level of PEEPe is subject to change as lung mechanics and
ventilatory requirements evolve.
In conclusion, PEEPe normally has no indication
in acute severe asthma during controlled ventilation. In
contrast, as soon as a mode of ventilation is selected that
allows the patient to spontaneously trigger the ventilator,
PEEPe can be applied and must be titrated gradually to
a level lower than PEEPi, based on patient comfort.
Administration of beta-adrenergic agents
As a first-line treatment of bronchoconstriction β-ad-
renergic agents are preferably given as repeated inhaled
doses rather than as continuous intravenous infusion due
to the faster onset of action and the lesser incidence of
adverse side effects with the former mode of administra-
tion [27, 28]. Aerosolized salbutamol can be delivered
via metered-dose inhalers (MDI) or nebulizers. MDI,
if possible with the adjunction of a spacer device, are
preferred to nebulizers because of easier manipulation,
more readily reproducible dose, quicker achievement of
maximal bronchodilatation and a lesser risk of bacterial
contamination [29, 30, 31, 32].
Humidification of inspired air
Humidification should be achieved with a heated cascade
humidifier, not with heat and moisture exchangers. The lat-
ter devices are undesirable for two reasons: First, they add
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to expiratory airway resistance, which would hardly be of
any help to reduce hyperinflation. Second, being inserted
between the endotracheal tube and the Y-piece of ventilator
tubing, they increase dead space and therefore contribute
unnecessarily to hypercapnia (see below).
Weaning
When exactly to start the weaning process is a matter of
clinical judgement. In our practice, once dynamic hyperin-
flation has abated sufficiently (as assessed by a substantial
resolution of wheezing on chest auscultation and a PEEPi
below 5 cmH2O), a trial of pressure-support ventilation is
initiated, followed if well tolerated by a standard weaning
procedure [20, 33, 34, 35]. In contrast with chronic
obstructive pulmonary disease [36], weaning is normally
rapidly achieved in patients with acute severe asthma [37].
Weaning difficulty in absence of persistent severe airway
obstruction must raise the suspicion of myopathy induced
by previous administration of neuromuscular blocking
agents and corticosteroids (see below).
Complications and mortality
In the first sizable series of severely asthmatic patients
managed with controlled hypoventilation for acute severe
asthma, published by Darioli and Perret [16] in 1984,
complications and mortality rates were considerably
lower than reported in previous studies which used
conventional mechanical ventilation. These favorable
results of controlled hypoventilation have been confirmed
repeatedly [19, 37, 38, 39, 40, 41, 42, 43].
The most frequently reported complication of me-
chanical ventilation in patients with acute severe asthma
is hemodynamic instability manifested as hypotension,
usually occurring at the initiation of ventilation and
related to the decrease in systemic venous return caused
by worsening of hyperinflation. This mechanism is easily
verified by temporarily disconnecting the patient from
the ventilator (60 s, under close monitoring of SpO2) and
documenting an immediate increase in blood pressure. In
such conditions ventilation should be resumed with lower
tidal volume and respiratory rate and adequate volume
expansion should rapidly follow. It is important to note
that when the decrease in blood pressure is unresponsive
to ventilator disconnection, tension pneumothorax must
be suspected.
Barotrauma is the second most frequently reported
complication. Controlled hypoventilation does not confer
complete protection in this context [19]. Although usually
not reported as a direct cause of mortality when rapidly
diagnosed and adequately treated, barotrauma can still be
life-threatening [43]. The mortality of patients mechani-
cally ventilated for acute severe asthma has been less than
10% in all studies published since 1990 except in two [37,
43]. A frequently reported cause of death is postanoxic
brain injury secondary to prehospital cardiac arrest.
Effects of CO2 retention
Except in patients with raised intracranial pressure or
severe myocardial depression the respiratory acidosis
induced by permissive hypercapnia is generally well
tolerated and does not need to be treated. This topic
has been exhaustively reviewed and is not discussed in
detail here [17]. In all ventilated asthmatics, in order to
reduce hypercapnia, we recommend maximally reducing
CO2 production by the use of sedation, analgesia, and
antipyretics. If these measures are deemed insufficient,
muscle relaxants may be considered. A clinical challenge
is presented by acute severe asthma culminating in
cardiorespiratory arrest with potential postanoxic injury,
which faces the clinician with the therapeutic dilemma of
brain protection vs. ventilator-induced lung injury. Blood
alkalinization, although not supported by strong clinical
data, may be considered in this context. Briefly, one may
use a slow infusion of sodium bicarbonate. However, too
rapid alkali administration in the context of suppressed
ventilatory drive may transiently raise the arterial PCO2,
thus worsening intracellular and cerebrospinal acidosis.
In addition, with severe respiratory acidosis very large
amounts of sodium bicarbonate may be required to sub-
stantially raise blood pH, potentially leading to volume
overload. Other buffers, such as tris-hydroxymethyl
aminomethane (tromethamine, Carbicarb), do not have
these disadvantages, but clinical experience with these
agents is quite limited [44].
Sedation and muscle paralysis
Controlled hypoventilation requires deep sedation. Ben-
zodiazepines can be safely used [19, 40]. Alternatively,
propofol may be preferred because of its bronchodilating
action [41, 45] but must be instituted with great caution
due to the risk of hypotension, particularly in hypovolemic
patients [46]. Ketamine may also be considered. In addi-
tion to anesthetic, sedative and analgesic effects, it exerts
a bronchodilating action via several pathways (adrenergic
stimulation, cholinergic and histaminic blockade) [47]. In
refractory acute severe asthma its use in anesthetic [48]
or infra-anesthetic [49, 50] doses has been associated with
reduced bronchospasm and favorable outcome. However,
this agent can stimulate tracheobronchial secretion and in-
crease intracranial pressure [47]. In view of the latter effect
ketamine should be withheld in presence of established or
suspected anoxic encephalopathy.
When trying to enforce controlled hypoventilation, the
addition of opioids to either benzodiazepines or propofol
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may help suppress the ventilatory drive, at times enabling
paralysis to be avoided. The natural opioid morphine can
cause allergic reactions and bronchoconstriction [51] and
thus should be avoided in acute severe asthma. Synthetic
opioids should be used instead, either fentanyl or remifen-
tanyl. The latter drug potently suppresses the ventilatory
drive [52] and has a rapid onset of action.
Despite the use of deep sedation patient-ventilator
asynchrony can be a problem that requires muscle paral-
ysis, particularly in the presence of acute hypercapnia.
Substantial data support a high frequency of complications
induced by neuromuscular-blocking agents (NMBA) in
mechanically ventilated asthmatics. In particular, diffuse
paresis of voluntary muscles has been noted on cessation
of NMBA administration, lasting from a few hours to
months, sometimes involving the respiratory muscles and
thus delaying ventilator weaning [53, 54, 55, 56]. This was
recently confirmed by a French retrospective study which
showed a higher frequency of postextubation muscle
weakness among mechanically ventilated asthmatics
treated with NMBA for more than 12 h in comparison
to similar patients who received sedation alone [57].
Because the great majority of cases occur following
combined treatment with NMBA and corticosteroids,
a deleterious interaction of these two classes of drugs
has been proposed [58]. Further commonly accepted risk
factors are the duration of muscle relaxation [59, 60] and
the cumulative dose of NMBA [61]. Electromyography
(EMG) typically shows acute myopathy confirmed by ele-
vated levels of creatine-phosphokinase and thick filament
necrosis noted on muscle biopsy [59, 60, 61]. In a study
by Leatherman and colleagues [59] all patients (18 of 20,
paralyzed for >24 h) who developed clinically significant
muscle weakness had acute myopathy when EMG was
performed. Considering the high probability that muscle
weakness developing following mechanical ventilation for
acute severe asthma is due to acute myopathy (rather than
polyneuropathy, which has never been well documented in
status asthmaticus), diagnostic confirmation with an EMG
is not urgent and may be restricted to protracted cases.
According to current recommendations by the American
Society of Critical Care Medicine, NMBA should be
given as intermittent intravenous boluses rather than as
a continuous infusion [54] to reduce the dose and duration
of administration [62]. To further serve this goal the
decision to repeat an NMBA bolus should only be made
when patient-ventilator asynchrony (a) reappears and (b)
cannot be suppressed by increasing the opioid dose. With
this strategy of NMBA administration we advocate that
neuromuscular monitoring with “train of four” nerve stim-
ulation becomes irrelevant and dispensable, independently
of the fact that its usefulness has been questioned in the
ICU setting [63, 64].
Therapeutic options in refractory acute severe
asthma
The main measures to relieve bronchial obstruction remain
the administration of inhaled β2-agonists and intravenous
corticosteroids. However, in refractory cases, some addi-
tional therapies might be tried, although not supported by
strong evidence. In these refractory cases severe airway
obstruction combined with controlled hypoventilation may
limit the effective delivery of inhaled bronchodilators. The
intravenous administration of these agents should then be
considered.
The administration of magnesium sulfate to nonin-
tubated asthmatic patients in an emergency department
either by aerosol (250 mmol/l) [65] or intravenously
(2 g in 30 min) [66] has recently been shown to have
powerful bronchodilating effects when used as an adjunct
to aerosolized β2-agonists. In five intubated asthmatics
Sydow and colleagues [67] found that high-dose (10–20 g
in 60 min) intravenous magnesium sulfate resulted in
a significant decrease in peak airway pressure and inspi-
ratory flow. Of note, these high doses were associated
with a threefold increase in serum magnesium levels
and with significant hypotension, requiring vasopressor
treatment in two patients. Based on these studies and
given the relatively low cost of this therapy we believe that
intravenous magnesium sulfate therapy should be used
in refractory acute severe asthma. In our experience the
following dose and schedule of administration is usually
safe: repeated doses of 2 g every 30 min, maximum
cumulative dose 10 g, under strict monitoring of serum
magnesium levels.
Breathing of helium-oxygen mixtures (HeO2) facili-
tates ventilation by reducing resistance to turbulent gas
flow [68]. In nonintubated asthmatic patients HeO2 breath-
ing increases peak expiratory flow rate and improves dys-
pnea scores [69, 70]. Three studies, one retrospective and
two prospective, were carried out in a total of 23 venti-
lated asthmatics and reported beneficial effects of HeO2
breathing (60–70% He, 30–40% O2) on oxygenation, air-
way resistance, and acute respiratory acidosis [71, 72, 73].
According to a meta-analysis, the beneficial effects of this
therapy seem most pronounced in the severest cases and
tend to wane after 1 h of administration [74]. It is important
to keep in mind that the FIO2 and particularly the tidal vol-
ume actually delivered to the patient may substantially dif-
fer from their set values. Correction factors were hence de-
veloped that can be applied to most ICU ventilators when
using HeO2 [75]. Careful reading of the report by Tassaux
et al. [75] is mandatory for anyone considering the use of
HeO2 in ventilated patients.
Finally, there are isolated reports on possible benefi-
cial bronchodilating effects of inhaled halogenated anes-
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thetics [76, 77]. However, their use in ventilated asthmatics
is logistically extremely cumbersome.
Noninvasive positive pressure ventilation
For the treatment of acute respiratory failure one may con-
sider noninvasive positive pressure ventilation (NIPPV)
as an option in asthmatic patients at risk for endotra-
cheal intubation due to progressive exhaustion. Two
prospective studies including a total of 47 such patients
who on admission were either normocapnic [78] or
hypercapnic [79] showed that a short trial of NIPPV
improves respiratory distress. Although NIPPV can be
effective in severe asthma, it should not unnecessarily
delay endotracheal intubation. Therefore from a practical
standpoint identification of which patients would most
benefit of NIPPV is crucial. Absolute contraindications
for the use of NIPPV in asthma are the same as in
other conditions [80], including emergency intubation
for cardiorespiratory resuscitation, hemodynamic and
electrocardiographic instability, life-threatening hypox-
emia, and an altered state of consciousness. The presence
of severe respiratory acidosis on hospital admission,
while not being per se a contraindication to NIPPV,
should alert the clinician to the high risk of endotracheal
intubation. In fact, among severe asthmatics admitted to
the ICU for acute respiratory failure it has been shown
that patients treated with NIPPV had less severe res-
piratory acidosis (mean PaCO2 53 ± 13 mmHg; mean
pH 7.28 ± 0.008) than those who eventually underwent
endotracheal intubation (mean PaCO2 89 ± 29 mmHg;
mean pH 7.05 ± 0.21) [81].
NIPPV can be started with low levels of inspi-
ratory pressure support (5–7 cmH2O) and PEEP
(3–5 cmH20, see previous discussion). Pressure sup-
port should be progressively increased (by 2 cmH2O
every 15 min), the goal being to reduce respiratory rate
below 25 breaths/minute, while keeping peak inspiratory
pressure below 25 cmH2O. Aerosolized bronchodila-
tors are easily administered through the ventilator
circuit [82].
Conclusion
As we have seen, guidelines for mechanical ventilation in
acute severe asthma are not supported by strong data in
the sense of evidence-based medicine. Indeed, it is striking
that the works which have most influenced present practice
in this area were all observational in nature and were car-
ried out on a limited number of patients [14, 15, 16, 19]. It
seems unlikely that a higher level of evidence will emerge
in the near future, due to both the relative rarity of intu-
bation and the general agreement regarding specific tech-
niques of ventilatory support in the acutely ill asthmatic.
Such consensus is based on firm pathophysiological un-
derstanding which nothing in the available data comes to
contradict.
In summary, mechanical ventilation is indicated in
asthmatic patients unresponsive to aggressive medical
treatment and in those admitted at an advanced stage of the
disease (i.e., altered level of consciousness, total fatigue,
severe respiratory distress). Such patients always have ex-
treme lung hyperinflation due to airway obstruction and to
the loss of lung elastic recoil. In these conditions striving
for normocapnia may be dangerous, first, worsening lung
hyperinflation with the risk of causing barotrauma and,
second, by inducing cardiovascular collapse. The aim of
controlled hypoventilation with permissive hypercapnia is
to reduce these potentially life-threatening side effects, by
using a pattern of low minute ventilation (≤ 10 l/min), tidal
volume (6–10 ml/kg ideal body weight), and respiratory
rate (10–14 cycles/min), taking care that expiratory time
be sufficient (≥ 4 s). Controlled hypoventilation requires
deep sedation, and, at least initially, muscle paralysis.
The prolonged use of neuromuscular blockers should
be avoided to limit the risk of ensuing myopathy. In the
absence of concomitant postanoxic injury, the short-term
prognosis of ventilated asthmatics is good.
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